Medicines & supplements – Current GIS Alerts 2026
Found 762 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Adnamil
Tests showed non-compliance with quality requirements for the parameters "Appearance" and "Resistance to crushing" ("Hardness"), as well as dust on tablets in blisters and hardness values exceeding the upper specification limit. Potencjalne skutki: abnormal release of the active substance or reduced treatment efficacy.
Atorvastatin Medical Valley
The product does not comply with quality requirements due to a failed appearance test; this quality defect may affect critical quality attributes of the medicinal product, especially during storage. Potential effects: reduced treatment efficacy, variability in drug action, possible adverse reactions.
Concor Cor 5
Stability studies showed an exceedance of the quality specification limit for the N-Nitroso-Bisoprolol (NBP) impurity content; further increase of this impurity level is expected during the product's shelf life. Potential effects: possible carcinogenic effects and complications from long-term exposure to a nitrosamine impurity.
Concor Cor 5
An exceedance of the quality specification limit for the content of the impurity N-Nitroso-Bisoprolol (NBP) was found in Concor Cor 5 mg tablets, with a tendency for further increase of this impurity level during the product's shelf-life. Potential effects: possible toxic and carcinogenic effects, especially with long-term use.
Concor 5
A breach of the quality specification limit was found for the content of the N-Nitroso-Bisoprolol (NBP) impurity in 5 mg bisoprolol fumarate tablets, indicating the presence of an undesired nitrosamine impurity forming during storage of the medicine. Potential effects: increased carcinogenic risk with long-term use of the medicine.
Concor Cor 5
The non-compliance consists in exceeding the quality specification limit for the content of the impurity N-Nitroso-Bisoprolol (NBP), which increases during storage of the tablets. Potential effects: increased risk of adverse reactions, including potential carcinogenic effects with long-term use.
Concor 5
The non-compliance consists in exceeding the specification limit for the content of the impurity N-nitroso-bisoprolol. Assessment of available stability data indicates that NBP will continue to form during the shelf-life. Potential effects: increased risk of carcinogenic effects with long-term use.
Concor Cor 5
The non-compliance consists in exceeding the quality specification limit for the content of the impurity N-nitroso-bisoprolol (NBP) in the finished film-coated tablets. Potencjalne skutki: increased risk of carcinogenic effects during long-term use of the medicine.
Concor 5
Exceedance of the quality specification limit for N-Nitroso-Bisoprolol impurity content in Concor 5 (bisoprolol fumarate), 5 mg tablets. Potential effects: possible increased risk of adverse reactions and harm to health with long-term use of the medicine.
Concor Cor 5
The non-conformity consists in exceeding the quality specification limit for the N-nitroso-bisoprolol (NBP) impurity content in Concor Cor 5 tablets; the NBP level increases during storage within the shelf-life. Potential effects: prolonged exposure to nitrosamine contamination, possible increased carcinogenic risk.
Concor Cor 5
An out-of-specification result was found for the content of the impurity N-Nitroso-bisoprolol (NBP), which increases over the product's shelf-life in batches manufactured with a specific excipient. Potencjalne skutki: increased risk of adverse effects and cancers with long-term use.
Libtayo
A quality defect was identified: incomplete crimping, which may lead to leakage and contamination of the product, potential transmission of an infectious agent, or underdosing during patient treatment. Potential effects: infection, lack of anticancer efficacy, treatment complications.
Bromiduo
Testing by the National Medicines Institute showed non-compliance with quality requirements for the Dose mass parameter (exceeding the upper specification limit), which may result in administration of an incorrect dose of the medicine during nebulisation. Potential effects: lack of treatment efficacy or increased adverse reactions related to overdose.
Atrodil Combo
Tests showed non-compliance with the registration dossier requirements for the Dose mass parameter, exceeding the upper limit of the quality specification, which means administration of a higher than declared drug dose. Potential effects: overdose of the medicine, increased adverse reactions, cardiac arrhythmias, tremor, complications in patients with cardiovascular disease.
Teicoplanin Pharmline
Quality testing showed in 1 of 20 solvent ampoules the presence of two particles visible to the naked eye, whereas the product should be practically free from particles visible to the naked eye. Potential effects: complications after intravenous administration, inflammatory reactions, particle embolism.
Teicoplanin Pharmline
The product does not meet quality requirements due to contamination with particles visible to the naked eye in the vial with powder, although it should be practically free from such particles. Potential effects: inflammatory reactions, vascular emboli, thrombotic complications during intravenous administration.
Bendamustine Glenmark
Out-of-specification result for the "active substance content" parameter was found - lower content of bendamustine hydrochloride, which may lead to a lack of the intended treatment efficacy. Potencjalne skutki: lack of effectiveness of anticancer therapy, worsening of the disease course.
Risperidone Teva
Testing by the National Medicines Institute showed that the product does not meet quality requirements due to an out-of-specification result for the release parameter at specified time points and temperature. Potencjalne skutki: lack of treatment efficacy, fluctuations in drug levels and poor symptom control.
Risperidone Teva
The product does not meet quality requirements due to an out-of-specification result for the release parameter at specified time points and temperature. Potential effects: lack of treatment efficacy or unpredictable medicinal effect.
Risperidone Teva
The product does not meet quality requirements due to an out-of-specification result for the release parameter at specific time points and temperatures, and irregularities in particle size analysis. Potencjalne skutki: reduced treatment efficacy or unpredictable adverse reactions.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.